Ayunova Pharmaceutical LLP

Gentamicin Injection BP

Gentamicin For Injection BP is a broad-spectrum aminoglycoside antibiotic used for the treatment of serious bacterial infections caused by Gram-negative and some Gram-positive organisms.

It works by inhibiting bacterial protein synthesis, effectively controlling infections in bloodstream, urinary tract, respiratory tract, skin, bones, and soft tissues.

Gentamicin injection is widely used in hospitals and critical care settings for severe infections where oral therapy is not feasible.

Each ml contains:

• Gentamicin Sulphate BP/USP – 40 mg/ml (or as per formulation)

• Excipients: Sterile water for injection, suitable buffer

• Treatment of severe Gram-negative infections (e.g., E. coli, Pseudomonas, Klebsiella)

• Management of severe Gram-positive infections (in combination therapy)

• Treatment of septicemia, urinary tract infections, respiratory infections, skin and soft tissue infections, bone and joint infections

• Perioperative prophylaxis in high-risk surgeries

• Administer via intravenous or intramuscular injection only

• Dose is individualized based on infection severity, patient age, weight, and renal function

• Monitor renal function and serum drug levels during therapy

• Use under strict medical supervision

• Vials: 2 ml / 5 ml / 10 ml / 20 ml (concentration: 40 mg/ml)

• Sterile, ready-for-injection formulation

• Box packaging with product information leaflet

• Store at 2–8°C

• Protect from light and freezing

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 10x1ml

Levofloxacin 250 mg Tablets BP

Levofloxacin 250 mg Tablets BP is a broad-spectrum fluoroquinolone antibiotic used for the treatment of bacterial infections caused by susceptible Gram-positive and Gram-negative bacteria.

• Levofloxacin – inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and cell growth.

• Highly effective in respiratory, urinary, skin, and soft tissue infections.

• Offers rapid absorption, high tissue penetration, and convenient dosing, making it suitable for both community and hospital use.

Each tablet contains:

• Levofloxacin BP/USP – 250 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Levofloxacin 250 mg Tablets are indicated for:

1. Respiratory Tract Infections

   • Community-acquired pneumonia, acute bacterial sinusitis, chronic bronchitis exacerbations

2. Urinary Tract Infections (UTIs)

   • Cystitis, pyelonephritis, prostatitis

3. Skin and Soft Tissue Infections

   • Cellulitis, wound infections, abscesses

4. Bone and Joint Infections

   • Osteomyelitis and septic arthritis caused by susceptible bacteria

5. Gastrointestinal Infections

   • Certain bacterial gastroenteritis caused by susceptible organisms

6. Other serious infections caused by susceptible bacteria as determined by the clinician

• Adults: One 250 mg tablet once daily or as prescribed

• Can be taken with or without food

• Drink plenty of fluids to prevent crystalluria

• Complete the full prescribed course to prevent resistance

• Dose adjustment may be needed in renal impairment

• Blister packs: 3 / 5 / 7 / 10 / 14 tablets per strip

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 250 mg

Ciprofloxacin 250 mg Tablets BP

Ciprofloxacin 250 mg Tablets BP is a broad-spectrum fluoroquinolone antibiotic used for the treatment of bacterial infections caused by susceptible Gram-negative and some Gram-positive organisms.

• Ciprofloxacin – inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and bacterial growth.

• Highly effective in respiratory, urinary, gastrointestinal, skin, and soft tissue infections.

• Offers rapid absorption and high tissue penetration, making it suitable for community and hospital use.

This antibiotic is widely used for mild to severe infections, especially when resistant or complicated bacteria are suspected.

Each tablet contains:

• Ciprofloxacin BP/USP – 250 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Ciprofloxacin 250 mg Tablets are indicated for:

1. Respiratory Tract Infections

   • Acute bacterial sinusitis, bronchitis, pneumonia

2. Urinary Tract Infections (UTIs)

   • Cystitis, pyelonephritis, prostatitis

3. Gastrointestinal Infections

   • Infectious diarrhea, typhoid, paratyphoid fever

4. Skin and Soft Tissue Infections

   • Cellulitis, abscesses, wound infections

5. Bone and Joint Infections

6. Anthrax Exposure (post-exposure prophylaxis)

7. Other serious infections caused by susceptible bacteria as determined by the clinician

• Adults: One 250 mg tablet twice daily or as prescribed

• Can be taken with or without food

• Drink plenty of fluids to prevent crystalluria

• Complete the full prescribed course to prevent resistance

• Dose adjustment may be needed in renal impairment

• Blister packs: 3 / 5 / 7 / 10 / 14 tablets per strip

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 DAYS
• Packaging Details: 250 mg

Ceftriaxone Sodium for Injection BP

Ceftriaxone Sodium for Injection BP is a broad-spectrum third-generation cephalosporin antibiotic used for the treatment of serious bacterial infections.

It works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Ceftriaxone is effective against both Gram-positive and Gram-negative bacteria, making it ideal for systemic infections, including respiratory, urinary tract, skin, bone, and intra-abdominal infections.

Each vial contains:

• Ceftriaxone Sodium BP – 250 mg / 500 mg / 1 g (as per variant)

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Ceftriaxone Sodium for Injection is indicated for:

1. Severe bacterial infections including:

   • Pneumonia, bronchitis, meningitis

   • Septicemia and bacteremia

   • Urinary tract infections (UTIs)

   • Bone and joint infections

   • Skin and soft tissue infections

   • Intra-abdominal infections

2. Surgical prophylaxis

3. Gonorrhea and other sexually transmitted infections

4. Empirical therapy for life-threatening infections before pathogen identification

• Adults: 1–2 g once or twice daily, depending on infection severity

• Children: 20–80 mg/kg/day, divided in one or two doses

• Route: IV or IM injection

• Administer over recommended infusion time and reconstitute as per guidelines

• Dose adjustment may be required in renal impairment

• Vials: 250 mg, 500 mg, 1 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 2mg

Piperacillin + Tazobactam for Injection BP

Piperacillin + Tazobactam for Injection BP is a broad-spectrum penicillin/beta-lactamase inhibitor combination used to treat serious and resistant bacterial infections.

• Piperacillin is an extended-spectrum penicillin effective against Gram-positive and Gram-negative bacteria.

• Tazobactam is a beta-lactamase inhibitor that protects Piperacillin from enzymatic degradation, enhancing its efficacy against beta-lactamase-producing bacteria, including Pseudomonas aeruginosa.

This combination is commonly used in hospital-acquired infections, ICU infections, and severe systemic infections, providing rapid and effective antibacterial action.

Each vial contains:

• Piperacillin BP – 2 g / 4 g / 8 g

• Tazobactam BP – 0.25 g / 0.5 g / 1 g

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Piperacillin + Tazobactam for Injection is indicated for:

1. Severe bacterial infections including:

   • Respiratory tract infections (hospital-acquired and ventilator-associated pneumonia)

   • Urinary tract infections (UTIs)

   • Intra-abdominal infections

   • Skin and soft tissue infections

   • Bone and joint infections

   • Septicemia and bacteremia

   • Gynecological infections

2. Hospital-acquired infections and resistant bacterial strains

3. Empirical therapy for life-threatening infections before pathogen identification

4. Surgical prophylaxis in high-risk or contaminated procedures

• Adults: 3.375–4.5 g (Piperacillin + Tazobactam) every 6–8 hours, depending on infection severity

• Children: 80–100 mg/kg/dose (Piperacillin component) every 6–8 hours

• Route: IV infusion over 30–60 minutes

• Dose adjustments may be required in renal impairment

• Vials: 2 g + 0.25 g, 4 g + 0.5 g, 8 g + 1 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 4.5mg

Meropenem for Injection BP

Meropenem for Injection BP is a broad-spectrum carbapenem antibiotic used for the treatment of serious bacterial infections, including those caused by multidrug-resistant pathogens.

Meropenem works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. It is effective against Gram-positive, Gram-negative, and anaerobic bacteria, making it ideal for complicated infections such as sepsis, pneumonia, intra-abdominal infections, urinary tract infections, skin and soft tissue infections, and meningitis.

Each vial contains:

• Meropenem BP – 500 mg / 1 g / 2 g (depending on variant)

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Meropenem for Injection is indicated for:

1. Severe bacterial infections including:

   • Complicated intra-abdominal infections

   • Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)

   • Septicemia and bacteremia

   • Urinary tract infections (UTIs)

   • Skin and soft tissue infections

   • Bone and joint infections

   • Meningitis

2. Empirical therapy for life-threatening infections before pathogen identification

3. Treatment of infections caused by multidrug-resistant organisms (MDROs)

• Adults: 500 mg–1 g every 8 hours, depending on infection severity

• Children: 10–40 mg/kg every 8 hours

• Route: IV infusion over 15–30 minutes

• Dose adjustments may be required in renal impairment

• Vials: 500 mg, 1 g, 2 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 1mg

Teicoplanin for Injection BP

Teicoplanin for Injection BP is a glycopeptide antibiotic used for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci.

Teicoplanin works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. It is highly effective against Gram-positive cocci and enterococci and is commonly used in hospital-acquired infections, sepsis, endocarditis, bone and joint infections, and skin and soft tissue infections.

Each vial contains:

• Teicoplanin BP – 200 mg / 400 mg / 600 mg

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Teicoplanin for Injection is indicated for:

1. Serious Gram-positive infections including:

   • Methicillin-resistant Staphylococcus aureus (MRSA) infections

   • Coagulase-negative staphylococcal infections

   • Enterococcal infections

   • Skin and soft tissue infections

   • Bone and joint infections (osteomyelitis)

   • Endocarditis

2. Hospital-acquired infections

3. Severe infections in patients allergic to penicillin

4. Sepsis and bacteremia caused by Gram-positive bacteria

• Adults: 400–800 mg once daily (loading dose may be given as per infection severity)

• Children: 6–10 mg/kg once daily

• Route: IV infusion or IM injection

• Administer slowly over recommended time; dose adjustment may be required in renal impairment

• Should be administered under medical supervision

• Vials: 200 mg / 400 mg / 600 mg per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 400mg

Colistimethate Sodium for Injection BP is a polymyxin antibiotic used for the treatment of severe infections caused by multidrug-resistant Gram-negative bacteria. It is the inactive prodrug of colistin, which is converted in vivo to active colistin that disrupts bacterial cell membranes, leading to bacterial death.

This sterile injectable formulation is intended for intravenous administration under specialist supervision, and is particularly valuable in intensive care units for treating infections resistant to conventional antibiotics.

Each vial contains:

• Colistimethate Sodium BP – 1 million IU / 2 million IU / 3 million IU

• Excipients: q.s. sterile water for injection

After reconstitution, it is ready for intravenous infusion.

• Severe infections caused by multidrug-resistant Gram-negative bacteria – e.g., Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae

• Septicemia and bloodstream infections

• Lower respiratory tract infections including ventilator-associated pneumonia (VAP)

• Urinary tract infections caused by resistant strains

• Skin and soft tissue infections caused by Gram-negative bacteria

• Intra-abdominal infections when resistant organisms are suspected

• Route: Intravenous (IV) infusion

• Adult Dose: Typically 2.5–5 mg/kg/day of colistin base activity (CBA), divided into 2–4 doses, adjusted per renal function

• Pediatric Dose: Weight-based, adjusted per clinical protocol

• Monitoring: Renal function, electrolytes, and clinical response; monitor for nephrotoxicity and neurotoxicity

⚠ Administer only under specialist supervision

• Available strengths: 1 million IU, 2 million IU, 3 million IU vials

• Sterile solution for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10DAYS
• Packaging Details: 2 MIU

Levofloxacin + Ornidazole Tablets BP – 1000 mg

Levofloxacin + Ornidazole Tablets BP is a broad-spectrum antibiotic and antiprotozoal combination used for the treatment of bacterial and protozoal infections.

• Levofloxacin (500 mg): A fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial replication and growth.

• Ornidazole (500 mg): A nitroimidazole derivative effective against anaerobic bacteria and protozoa, disrupting DNA synthesis in susceptible organisms.

This combination provides rapid and effective relief from mixed infections, making it useful in respiratory, gastrointestinal, genitourinary, and skin infections caused by susceptible bacteria and protozoa.

Each film-coated tablet contains:

• Levofloxacin BP – 500 mg

• Ornidazole BP – 500 mg

• Excipients: q.s.

• Respiratory tract infections (pneumonia, bronchitis)

• Gastrointestinal infections (diarrhea, dysentery, gastroenteritis)

• Urinary tract infections (UTIs)

• Genitourinary infections (trichomoniasis, bacterial vaginosis)

• Skin and soft tissue infections

• Mixed aerobic and anaerobic bacterial infections

• Prevention of secondary infections in post-surgical cases

• Route: Oral

• Usual Dose: 1 tablet twice daily, or as prescribed by the physician

• Administration: Take with water, preferably after meals to reduce gastrointestinal irritation

⚠ Complete the full course of therapy to prevent resistance
⚠ Use with caution in patients with renal or hepatic impairment
⚠ Contraindicated in patients with hypersensitivity to fluoroquinolones or nitroimidazoles

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1000 mg

Piperacillin and Tazobactam Injection is a broad-spectrum β-lactam/β-lactamase inhibitor combination used to treat serious bacterial infections. Piperacillin, a penicillin-class antibiotic, inhibits bacterial cell wall synthesis, while Tazobactam inhibits β-lactamase enzymes that degrade β-lactam antibiotics, thereby extending Piperacillin’s spectrum. This sterile formulation is intended for intravenous administration under medical supervision.

Each vial contains:

• Piperacillin Sodium IP – 4 g

• Tazobactam Sodium IP – 0.5 g

• Dosage Form: Powder for reconstitution to injection/infusion

• Excipients: q.s.

(Note: Strength can vary depending on product – commonly 2 g/0.25 g, 4 g/0.5 g, or 3.375 g/0.5 g)

Piperacillin and Tazobactam Injection is indicated for:

• Severe respiratory tract infections (community-acquired or hospital-acquired pneumonia)

• Complicated intra-abdominal infections

• Complicated urinary tract infections

• Skin and soft tissue infections

• Septicemia and bloodstream infections

• Infections caused by β-lactamase producing organisms

• For intravenous use only

• Reconstitute and further dilute before administration as per protocol

• Dosage and duration should be determined by a registered medical practitioner based on infection severity and renal function

• Broad-spectrum antibiotic combination

• Effective against β-lactamase producing pathogens

• Suitable for critical care and hospital settings

• Sterile, high-quality formulation

• Store below 25°C

• Protect from light

• Do not freeze

• Keep out of reach of children

• Pack Type: Vial

• Pack Size: 1 vial

• Strength Examples: 2 g/0.25 g, 4 g/0.5 g, 3.375 g/0.5 g

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10DAYS
• Packaging Details: Tazar 4.5G

TEXOPLAN 200 Injection

Teicoplanin for Injection BP

200 mg

TEXOPLAN 200 is a broad-spectrum glycopeptide antibiotic containing Teicoplanin, specially formulated for the treatment of serious Gram-positive bacterial infections. It is highly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant organisms.

TEXOPLAN 200 is widely used in hospital and critical care settings, including ICU and surgical units, due to its excellent tissue penetration, long half-life, and convenient dosing schedule.

Each vial contains:

• Teicoplanin BP – 200 mg

• Sterile excipients – q.s.

• Treatment of severe Gram-positive bacterial infections

• Infections caused by MRSA and penicillin-resistant organisms

• Skin and soft tissue infections

• Bone and joint infections (osteomyelitis, septic arthritis)

• Respiratory tract infections

• Urinary tract infections caused by Gram-positive bacteria

• Bloodstream infections (septicemia)

• Endocarditis caused by susceptible organisms

• Hospital-acquired and ICU-acquired infections

• Surgical site infections

• Infections in immunocompromised patients

• Route: Intravenous (IV) or Intramuscular (IM)

• Dosage: As directed by the physician

• Reconstitution: With Sterile Water for Injection as per guidelines

⚠ For hospital use only
⚠ To be administered under medical supervision

Teicoplanin inhibits bacterial cell wall synthesis, leading to bactericidal activity against susceptible Gram-positive organisms.

• Single vial pack

• Lyophilized powder for injection

• Secure, tamper-evident packaging suitable for export and institutional supply

• Store below 25°C

• Protect from light

• Do not freeze

• Use immediately after reconstitution

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 200mg

STEF-AV Injection is a combination of Ceftazidime (a third-generation cephalosporin antibiotic) and Avibactam (a non-β-lactam β-lactamase inhibitor). This advanced formulation is used for the treatment of serious and complicated bacterial infections caused by susceptible Gram-negative organisms, including multidrug-resistant strains. The product is supplied as a sterile powder for concentrate for solution for intravenous infusion after reconstitution and dilution.

Each vial contains:

• Ceftazidime IP – 2.0 g

• Avibactam Sodium IP – 0.5 g

• Total Strength: 2.5 g

• Dosage Form: Powder for concentrate for solution for infusion

STEF-AV Injection is indicated for the treatment of:

• Complicated urinary tract infections (cUTIs)

• Complicated intra-abdominal infections (cIAIs)*

• Hospital-acquired pneumonia (HAP)

• Ventilator-associated pneumonia (VAP)

• Serious Gram-negative bacterial infections caused by resistant organisms

*Used in combination with metronidazole where appropriate.

• For intravenous (IV) infusion only

• Must be reconstituted and further diluted before administration

• Dosage and duration should be determined by a registered medical practitioner based on infection severity and renal function

• Advanced antibiotic + β-lactamase inhibitor combination

• Effective against multidrug-resistant Gram-negative bacteria

• Suitable for critical care and hospital use

• Stable powder formulation for infusion

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

• Strength: 2.5 g

• Pack Type: Glass vial

• Pack Size: 1 vial

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 2.5gm

PIROTAZ 2.25 Injection is a broad-spectrum antibiotic combination of Piperacillin and Tazobactam, used for the treatment of various moderate to severe bacterial infections. The combination enhances antibacterial activity by inhibiting beta-lactamase enzymes, making it effective against resistant organisms. It is supplied as a sterile dry powder for intravenous administration after reconstitution.

Each vial contains:

• Piperacillin Sodium IP – 2.0 g

• Tazobactam Sodium IP – 0.25 g

• Total Strength: 2.25 g

• Dosage Form: Dry powder for injection

PIROTAZ 2.25 Injection is used in the treatment of:

• Respiratory tract infections

• Urinary tract infections (UTIs)

• Intra-abdominal infections

• Skin and soft tissue infections

• Gynecological infections

• Septicemia

• Hospital-acquired infections

• Administered by intravenous (IV) route only

• Dosage and duration to be determined by a registered medical practitioner based on infection severity

• Broad-spectrum antibiotic combination

• Effective against Gram-positive, Gram-negative & anaerobic bacteria

• Helps in managing resistant infections

• Suitable for hospital and clinical use

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

• Strength: 2.25 g

• Pack Type: Glass vial

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 2.25gm

MAXOPEN-500 Injection contains Meropenem, a broad-spectrum carbapenem antibiotic effective against a wide range of Gram-positive, Gram-negative and anaerobic bacteria. It is commonly used for the treatment of severe and life-threatening infections, especially those caused by resistant organisms. The injection is supplied as a sterile dry powder for intravenous administration after reconstitution.

Each vial contains:

• Meropenem IP – 500 mg

• Sterile excipients – q.s.

• Dosage Form: Dry powder for injection

MAXOPEN-500 Injection is indicated for the treatment of:

• Severe bacterial infections

• Lower respiratory tract infections

• Urinary tract infections (UTIs)

• Intra-abdominal infections

• Skin and soft tissue infections

• Septicemia

• Meningitis

• Hospital-acquired and resistant infections

• For intravenous (IV) use only

• To be reconstituted with appropriate diluent before administration

• Dosage and duration to be determined by a registered medical practitioner based on severity of infection

• Broad-spectrum carbapenem antibiotic

• Highly effective against resistant bacteria

• Suitable for critical care and hospital use

• IP grade formulation

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

• Strength: 500 mg

• Pack Type: Glass vial

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 500mg

Colistimethate Sodium for Injection IP is a polymyxin antibiotic used in the treatment of serious and life-threatening Gram-negative bacterial infections, particularly those caused by multidrug-resistant organisms. It is commonly used in intensive care settings for infections where other antibiotics are ineffective. The injection is intended for intravenous use under strict medical supervision.

Each vial contains:

• Colistimethate Sodium IP – Equivalent to 0.5 Million IU

• Dosage Form: Powder for solution for injection

Colistimethate Sodium Injection is indicated for the treatment of:

• Severe infections caused by multidrug-resistant Gram-negative bacteria

• Hospital-acquired and ventilator-associated pneumonia

• Bloodstream infections (septicemia)

• Urinary tract infections

• Intra-abdominal infections

• Infections caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae

• For intravenous use (and as directed, other routes as prescribed)

• Dosage and duration strictly as prescribed by a registered medical practitioner

• Reconstitution and dilution should be performed as per standard medical guidelines

• Effective against multidrug-resistant Gram-negative pathogens

• Critical care antibiotic

• IP-grade formulation

• Suitable for ICU and hospital use

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 0.5 Million IU

• Dosage Form: Powder for injection

• Pack Type: Single vial with carton

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 0.5 million IU

TEXOPLAN 400 Injection

Teicoplanin for Injection BP

400 mg

TEXOPLAN 400 is a high-strength glycopeptide antibiotic injection containing Teicoplanin 400 mg, indicated for the treatment of severe and life-threatening Gram-positive bacterial infections. It is especially effective against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant Gram-positive organisms.

TEXOPLAN 400 is commonly used in ICU, critical care, and hospital settings, offering excellent efficacy, prolonged half-life, and convenient once-daily dosing.

Each vial contains:

• Teicoplanin BP – 400 mg

• Sterile excipients – q.s.

• Treatment of serious Gram-positive bacterial infections

• Infections caused by MRSA and other resistant organisms

• Skin and soft tissue infections

• Bone and joint infections (osteomyelitis, septic arthritis)

• Lower and upper respiratory tract infections

• Urinary tract infections due to Gram-positive bacteria

• Bloodstream infections (septicemia)

• Endocarditis caused by susceptible organisms

• Hospital-acquired and ICU-associated infections

• Post-surgical and wound infections

• Infections in immunocompromised patients

• Route: Intravenous (IV) or Intramuscular (IM)

• Dosage: As prescribed by the physician

• Reconstitution: With Sterile Water for Injection as per standard protocol

⚠ To be administered under medical supervision
⚠ For hospital and institutional use only

Teicoplanin inhibits bacterial cell wall synthesis, resulting in bactericidal activity against susceptible Gram-positive pathogens.

• Single vial with or without diluent

• Lyophilized powder for injection

• Tamper-proof, export-quality packaging

• Store below 25°C

• Protect from light

• Do not freeze

• Use reconstituted solution immediately

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 400 mg

Xylistin-N 1 MIU is a sterile colistimethate sodium injection used for the treatment of serious and life-threatening infections caused by multidrug-resistant Gram-negative bacteria. Colistimethate sodium is a polymyxin antibiotic reserved for critical infections where other antibiotics are ineffective. This formulation is widely used in ICU and hospital settings under strict medical supervision.

Each dry vial contains:

• Colistimethate Sodium IP – Equivalent to 1 Million IU (1 MIU)

• Dosage Form: Powder for solution for injection

Xylistin-N Injection is indicated for the treatment of:

• Severe infections caused by multidrug-resistant Gram-negative organisms

• Hospital-acquired pneumonia (HAP)

• Ventilator-associated pneumonia (VAP)

• Septicemia

• Urinary tract infections

• Intra-abdominal infections

• Infections caused by Acinetobacter, Pseudomonas, and Klebsiella species

• For intravenous use (other routes only if prescribed)

• Dosage and duration strictly as directed by a registered medical practitioner

• Reconstitution and dilution to be done as per standard clinical guidelines

• Effective against multidrug-resistant Gram-negative bacteria

• Critical-care antibiotic

• IP-grade formulation

• Suitable for ICU and hospital use

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Strength: 1 Million IU

• Dosage Form: Dry powder for injection

• Pack Type: 1 vial with carton

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1 MIU

Teicoplanin Injection 400 mg is a broad-spectrum glycopeptide antibiotic used for the treatment of serious Gram-positive bacterial infections. It is effective against organisms resistant to other antibiotics and is commonly used in hospital and clinical settings. The injection is supplied as a sterile lyophilized powder intended for intravenous or intramuscular administration after reconstitution.

• Teicoplanin IP – 400 mg

• Sterile excipients – q.s.

• Dosage Form: Lyophilized powder for injection

Teicoplanin Injection is used in the treatment of:

• Severe Gram-positive bacterial infections

• Septicemia

• Infective endocarditis

• Bone and joint infections

• Skin and soft tissue infections

• Respiratory tract infections

• Infections caused by methicillin-resistant Staphylococcus aureus (MRSA)

• Dosage should be determined by a qualified healthcare professional based on the type and severity of infection.

• Administered by IV or IM route after reconstitution with suitable diluent.

• Broad-spectrum glycopeptide antibiotic

• Effective against resistant Gram-positive bacteria

• Suitable for hospital and institutional use

• Long half-life allowing less frequent dosing

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 600mg

Colistimethate Sodium Injection IP 2 Million IU is a broad-spectrum polymyxin antibiotic used for the treatment of severe infections caused by multidrug-resistant Gram-negative bacteria. It is commonly administered in hospitalized patients where other antibiotics are ineffective. The injection is supplied as a sterile, white to off-white lyophilized powder for reconstitution before intravenous or intramuscular administration.

Each vial contains:

• Colistimethate Sodium IP equivalent to 2 Million IU

• Excipients: q.s.

Colistimethate Sodium Injection is used in the treatment of serious bacterial infections such as:

• Hospital-acquired pneumonia

• Ventilator-associated pneumonia

• Septicemia (bloodstream infections)

• Complicated urinary tract infections

• Intra-abdominal infections

• Skin and soft tissue infections

• Infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella species and other resistant Gram-negative organisms

• Dosage as directed by the physician

• Administered via intravenous (IV) or intramuscular (IM) route after reconstitution

• Dose adjustment may be required in patients with renal impairment

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Single vial pack

• Strength: 2 Million IU

• As per manufacturer’s label

• For hospital use only

• Use under strict medical supervision

• Monitor renal function during therapy

• Not recommended for patients with known hypersensitivity to polymyxins

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 2 MIU

Colistimethate Sodium Injection IP 3 Million IU is a potent polymyxin antibiotic used for the management of severe infections caused by multidrug-resistant Gram-negative bacteria. It is primarily indicated in critical care settings where alternative antibiotics are ineffective. The injection is supplied as a sterile, lyophilized powder that must be reconstituted before intravenous or intramuscular administration.

Each vial contains:

• Colistimethate Sodium IP equivalent to 3 Million IU

• Excipients: q.s.

Used in the treatment of serious bacterial infections including:

• Hospital-acquired pneumonia (HAP)

• Ventilator-associated pneumonia (VAP)

• Septicemia

• Complicated urinary tract infections

• Intra-abdominal infections

• Skin and soft tissue infections

• Infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella spp. and other resistant Gram-negative organisms

• Dosage and duration as prescribed by a physician

• Administered via intravenous (IV) or intramuscular (IM) route after reconstitution

• Dose adjustment may be necessary in patients with renal impairment

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

• Single-dose vial

• Strength: 3 Million IU

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 3 MIU

Colistimethate Sodium Injection IP 4.5 Million IU is a broad-spectrum polymyxin antibiotic indicated for the treatment of severe and life-threatening infections caused by multidrug-resistant Gram-negative bacteria. It is commonly used in critical care and hospital settings when other antibiotics fail. The product is supplied as a sterile, white to off-white lyophilized powder for reconstitution prior to intravenous or intramuscular administration.

Each vial contains:

• Colistimethate Sodium IP equivalent to 4.5 Million IU

• Excipients: q.s.

Used in the treatment of serious infections such as:

• Hospital-acquired pneumonia (HAP)

• Ventilator-associated pneumonia (VAP)

• Septicemia / bloodstream infections

• Complicated urinary tract infections

• Intra-abdominal infections

• Skin and soft tissue infections

• Infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella species, and other resistant Gram-negative organisms

• Dosage and duration as prescribed by a physician

• Administered by intravenous (IV) or intramuscular (IM) route after reconstitution

• Dose adjustment may be required in patients with renal impairment

• Store below 25°C

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

• Single-dose vial

• Strength: 4.5 Million IU

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 4.5 MIU

Cibinqo® 100 mg Film-Coated Tablets contain Abrocitinib, a selective Janus Kinase 1 (JAK1) inhibitor used for the treatment of moderate to severe atopic dermatitis (eczema) in adults and adolescents who require systemic therapy. By selectively inhibiting JAK1-mediated signaling, Cibinqo helps reduce inflammation, itching, and skin lesions, leading to significant improvement in disease control and quality of life.

Each film-coated tablet contains:

• Abrocitinib – 100 mg

• Excipients – q.s.

Cibinqo 100 mg Tablets are indicated for:

• Moderate to severe atopic dermatitis (eczema)

• Patients with inadequate response or intolerance to other systemic treatments

• Long-term disease management under dermatologist supervision

• Oral administration

• Dose as prescribed by the treating physician

• Swallow tablet whole with water

• Can be taken with or without food

• Dose adjustments may be required based on renal function, age, and clinical response

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

• Strip or bottle pack

• Strength: 100 mg film-coated tablets

Additional Information:

• Production Capacity: 10000
• Delivery Time: 10days
• Packaging Details: 100 mg

Mupirocin 2% Cream / Ointment

Mupirocin 2% Cream/Ointment is a topical antibacterial agent used for the treatment of skin infections caused by Gram-positive bacteria, including Staphylococcus aureus and Streptococcus species. It effectively inhibits bacterial protein synthesis, providing rapid relief from redness, swelling, and pus formation associated with localized skin infections.

This formulation is widely used in hospitals, clinics, and dermatology practices for conditions like impetigo, folliculitis, and minor wound infections.

Each gram contains:

• Mupirocin BP/USP – 2% w/w

• Excipients: Suitable cream or ointment base

(Exact composition may vary slightly depending on manufacturer.)

• Treatment of impetigo and superficial skin infections

• Management of folliculitis and infected wounds

• Topical therapy for minor cuts, abrasions, and burns prone to infection

• Prevention of bacterial colonization in skin lesions

• Symptomatic relief of redness, swelling, and discharge due to infection

• Apply a thin layer to the affected area 2–3 times daily

• Cover with sterile dressing if required

• Use for the prescribed duration even if symptoms improve

• Avoid contact with eyes and mucous membranes

• For external use only

• Tubes: 10 g / 15 g / 20 g / 30 g / 50 g

• Cream or ointment form as per requirement

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 20g

Gentamicin 0.1% Cream / Ointment

Gentamicin 0.1% Cream/Ointment is a topical antibiotic formulation used for the treatment of bacterial skin infections. It works by inhibiting bacterial protein synthesis, providing effective relief from redness, swelling, and pus formation associated with minor skin infections, cuts, and abrasions.

Available in both cream and ointment forms, it ensures easy application and rapid action, suitable for hospitals, clinics, and home care.

Each gram contains:

• Gentamicin Sulfate BP/USP – 0.1% w/w

• Excipients: Suitable cream or ointment base

(Exact composition may vary slightly depending on manufacturer.)

• Treatment of superficial bacterial skin infections

• Management of minor cuts, abrasions, and wounds

• Topical therapy for burns prone to infection

• Prevention of bacterial colonization in skin lesions

• Relief from redness, swelling, and discharge due to infection

• Apply a thin layer to the affected area 2–3 times daily

• Cover with sterile dressing if required

• Avoid contact with eyes and mucous membranes

• For external use only

• Use as directed by a healthcare professional

• Tubes: 10 g / 15 g / 20 g / 30 g / 50 g

• Cream or ointment form as per requirement

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 20G

Clindamycin 1% Topical Gel

Clindamycin 1% Topical Gel is a broad-spectrum topical antibiotic used for the treatment of acne vulgaris and other superficial bacterial skin infections. It works by inhibiting bacterial protein synthesis, reducing the growth of Propionibacterium acnes and other Gram-positive bacteria, thereby controlling inflammation, redness, and pus formation.

This gel is suitable for dermatology clinics and home use, offering effective topical antibacterial therapy with minimal systemic absorption.

Each gram contains:

• Clindamycin Phosphate BP/USP – 1% w/w

• Excipients: Suitable gel base

• Treatment of mild to moderate acne vulgaris

• Management of superficial bacterial skin infections

• Reduces inflammation, redness, and pustules associated with acne

• Supportive therapy for skin conditions prone to bacterial infection

• Apply a thin layer to the affected area once or twice daily as directed

• Gently massage until absorbed

• Avoid contact with eyes, mucous membranes, and broken skin

• Continue treatment for the prescribed duration for best results

• Tubes: 15 g / 30 g / 50 g / 100 g

• Gel form for easy topical application

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children.

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 20g

Mupirocin 2% + Metronidazole 0.75% Cream / Ointment

Mupirocin + Metronidazole Cream/Ointment is a combination topical preparation offering potent antibacterial and antiprotozoal action for the treatment of infected skin conditions.

• Mupirocin 2% – a topical antibiotic effective against Gram-positive bacteria, particularly Staphylococcus aureus, helping to treat and prevent bacterial skin infections.

• Metronidazole 0.75% – a topical agent effective against anaerobic bacteria and protozoal infections, reducing inflammation and bacterial load.

This combination is ideal for infected wounds, ulcers, acne complications, and rosacea, providing rapid relief from inflammation, redness, and infection.

Each gram contains:

• Mupirocin BP/USP – 2% w/w

• Metronidazole BP/USP – 0.75% w/w

• Excipients: Suitable cream or ointment base

• Treatment of bacterial and protozoal skin infections

• Management of infected wounds, ulcers, and acne complications

• Relief from redness, swelling, and pus formation

• Supportive therapy for rosacea and inflammatory skin conditions

• Apply a thin layer to the affected area 2–3 times daily or as directed

• Gently massage until absorbed

• Avoid contact with eyes and mucous membranes

• Use under medical supervision

• Tubes: 10 g / 15 g / 20 g / 30 g / 50 g

• Cream or ointment form for easy application

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 Days
• Packaging Details: 20g

Clindamycin 1% + Nicotinamide 4% Cream / Ointment

Clindamycin + Nicotinamide Cream/Ointment is a combination topical formulation designed for the treatment of acne vulgaris and inflammatory skin conditions.

• Clindamycin 1% – a topical antibiotic that reduces Propionibacterium acnes, preventing bacterial proliferation and infection.

• Nicotinamide 4% – a form of Vitamin B3 that reduces inflammation, regulates sebum production, and promotes skin barrier function.

This dual-action therapy provides effective antibacterial and anti-inflammatory benefits, helping to reduce acne lesions, redness, and irritation for clearer skin.

Each gram contains:

• Clindamycin Phosphate BP/USP – 1% w/w

• Nicotinamide BP/USP – 4% w/w

• Excipients: Suitable cream or ointment base

• Treatment of mild to moderate acne vulgaris

• Reduces papules, pustules, redness, and inflammation

• Helps control seborrhea and oily skin

• Supports healthy skin barrier and faster recovery

• Apply a thin layer to the affected area once or twice daily, as prescribed

• Avoid contact with eyes, lips, and mucous membranes

• Use sunscreen during the day to protect sensitive skin

• Continue treatment for the full prescribed duration

• Tubes: 15 g / 30 g / 50 g / 100 g

• Cream or ointment form for easy topical application

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 20g

Cefuroxime Axetil 250 mg Tablets BP

Cefuroxime Axetil 250 mg Tablets BP is a second-generation cephalosporin antibiotic used for the treatment of a wide range of bacterial infections.

• Cefuroxime Axetil – a prodrug of cefuroxime, it inhibits bacterial cell wall synthesis, leading to bacterial cell death.

• Effective against Gram-positive and Gram-negative bacteria, including β-lactamase-producing strains.

• It provides high oral bioavailability and is suitable for both community and hospital infections.

This antibiotic is commonly prescribed for respiratory, urinary, ENT, skin, and soft tissue infections.

Each tablet contains:

• Cefuroxime Axetil BP/USP – 250 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Cefuroxime Axetil 250 mg Tablets are indicated for:

1. Respiratory Tract Infections

   • Acute sinusitis, bronchitis, pneumonia

2. ENT Infections

   • Otitis media, tonsillitis, pharyngitis

3. Urinary Tract Infections

   • Cystitis, pyelonephritis

4. Skin and Soft Tissue Infections

   • Cellulitis, wound infections, abscesses

5. Bone and Joint Infections

6. Gonorrhea and other sexually transmitted infections caused by susceptible bacteria

• Adults: One tablet twice daily or as prescribed

• Take with food to enhance absorption

• Complete the full course of therapy to prevent resistance

• Adjust dosage in renal impairment

• Blister packs: 10 / 14 / 20 / 28 tablets per strip

• Boxes with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 250 mg

Azithromycin 250 mg Tablets BP

Azithromycin 250 mg Tablets BP is a broad-spectrum macrolide antibiotic used for the treatment of bacterial infections caused by susceptible organisms.

• Azithromycin – inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing bacterial growth.

• Highly effective against respiratory, ENT, skin, and sexually transmitted infections.

• Offers once-daily dosing due to its long half-life and good tissue penetration, enhancing patient compliance.

This antibiotic is commonly used in community and hospital settings for the treatment of mild to moderate infections.

Each tablet contains:

• Azithromycin Dihydrate BP/USP – 250 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Azithromycin 250 mg Tablets are indicated for:

1. Respiratory Tract Infections

   • Acute bacterial sinusitis, pharyngitis, tonsillitis, bronchitis, pneumonia

2. ENT Infections

   • Otitis media, tonsillitis

3. Skin and Soft Tissue Infections

   • Cellulitis, abscesses, wound infections

4. Sexually Transmitted Infections

   • Chlamydia trachomatis infections, urethritis, cervicitis

5. Mycobacterial Infections

   • Part of combination therapy for MAC (Mycobacterium avium complex) infections in immunocompromised patients

6. Other susceptible bacterial infections

• Adults: One 250 mg tablet once daily or as prescribed

• Can be taken with or without food

• Complete the full course even if symptoms improve

• Dose adjustment may be required in renal or hepatic impairment

• Blister packs: 3 / 5 / 6 / 10 / 14 tablets per strip

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 DAYS
• Packaging Details: 250 mg

Doxycycline 100 mg Tablets BP

Doxycycline 100 mg Tablets BP is a broad-spectrum tetracycline antibiotic used for the treatment and prevention of bacterial infections.

• Doxycycline – inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing bacterial growth.

• Effective against Gram-positive, Gram-negative, and atypical bacteria.

• Offers good oral absorption, long half-life, and tissue penetration, making it suitable for once or twice daily dosing.

Doxycycline is widely used in respiratory, urinary, dermatological, and sexually transmitted infections, as well as for malaria prophylaxis.

Each tablet contains:

• Doxycycline Hyclate BP/USP – 100 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Doxycycline 100 mg Tablets are indicated for:

1. Respiratory Tract Infections

   • Pneumonia, bronchitis, sinusitis

2. Urinary Tract Infections (UTIs)

3. Skin and Soft Tissue Infections

   • Acne vulgaris, cellulitis, wound infections

4. Sexually Transmitted Infections (STIs)

   • Chlamydia, syphilis, gonorrhea (as per guidelines)

5. Vector-Borne and Zoonotic Infections

   • Malaria prophylaxis, rickettsial infections, leptospirosis

6. Other Infections

   • Lyme disease, periodontal infections, and other susceptible bacterial infections

• Adults: One 100 mg tablet once or twice daily as prescribed

• Take with a full glass of water and avoid lying down immediately after

• Complete the full course even if symptoms improve

• Adjust dosage in renal or hepatic impairment

• Blister packs: 10 / 14 / 20 / 28 tablets per strip

• Box packaging with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 100 mg

Cefotaxime for Injection BP

Cefotaxime for Injection BP is a broad-spectrum third-generation cephalosporin antibiotic used for the treatment of serious bacterial infections.

It works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. Cefotaxime is effective against both Gram-positive and Gram-negative bacteria, making it ideal for respiratory tract infections, urinary tract infections, sepsis, skin and soft tissue infections, intra-abdominal infections, and meningitis.

Each vial contains:

• Cefotaxime Sodium BP – 250 mg / 500 mg / 1 g / 2 g (depending on variant)

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Cefotaxime for Injection is indicated for:

1. Severe bacterial infections such as:

   • Pneumonia and lower respiratory tract infections

   • Septicemia and bacteremia

   • Urinary tract infections (UTIs)

   • Skin and soft tissue infections

   • Bone and joint infections

   • Intra-abdominal infections

   • Meningitis

2. Surgical prophylaxis

3. Empirical therapy for life-threatening infections before pathogen identification

• Adults: 1–2 g every 8–12 hours, depending on infection severity

• Children: 50–200 mg/kg/day in divided doses

• Route: IV or IM injection

• Administer over recommended infusion time and follow reconstitution guidelines

• Dose adjustment may be needed in renal impairment

• Vials: 250 mg, 500 mg, 1 g, 2 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from moisture and light

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1mg

Ceftazidime for Injection BP

Ceftazidime for Injection BP is a third-generation cephalosporin antibiotic with a broad spectrum of activity, particularly effective against Gram-negative bacteria including Pseudomonas aeruginosa.

It works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. Ceftazidime is commonly used in the treatment of serious infections like respiratory tract infections, urinary tract infections, septicemia, skin and soft tissue infections, bone and joint infections, and meningitis.

Each vial contains:

• Ceftazidime Sodium BP – 250 mg / 500 mg / 1 g / 2 g (depending on variant)

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Ceftazidime for Injection is indicated for:

1. Severe bacterial infections including:

   • Pneumonia and lower respiratory tract infections

   • Septicemia and bacteremia

   • Urinary tract infections (UTIs)

   • Skin and soft tissue infections

   • Bone and joint infections

   • Intra-abdominal infections

   • Meningitis

2. Empirical therapy for life-threatening infections before pathogen identification

3. Surgical prophylaxis in high-risk procedures

• Adults: 1–2 g every 8–12 hours depending on infection severity

• Children: 50–150 mg/kg/day in divided doses

• Route: IV or IM injection

• Administer over recommended infusion time and follow proper reconstitution guidelines

• Dose adjustments may be needed in renal impairment

• Vials: 250 mg, 500 mg, 1 g, 2 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 2mg

Cefoperazone for Injection BP

Cefoperazone for Injection BP is a third-generation cephalosporin antibiotic with broad-spectrum activity, particularly effective against Gram-negative bacteria including Pseudomonas species.

It works by inhibiting bacterial cell wall synthesis, resulting in cell death. Cefoperazone is widely used for severe systemic infections such as respiratory tract infections, urinary tract infections, sepsis, skin and soft tissue infections, intra-abdominal infections, bone and joint infections, and meningitis.

Each vial contains:

• Cefoperazone Sodium BP – 500 mg / 1 g / 2 g (depending on variant)

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Cefoperazone for Injection is indicated for:

1. Severe bacterial infections including:

   • Pneumonia and lower respiratory tract infections

   • Septicemia and bacteremia

   • Urinary tract infections (UTIs)

   • Skin and soft tissue infections

   • Bone and joint infections

   • Intra-abdominal infections

   • Meningitis

2. Empirical therapy for life-threatening infections before pathogen identification

3. Surgical prophylaxis in high-risk procedures

• Adults: 1–2 g every 12–24 hours depending on infection severity

• Children: 50–100 mg/kg/day in divided doses

• Route: IV or IM injection

• Administer over recommended infusion time and follow proper reconstitution guidelines

• Dose adjustments may be needed in renal or hepatic impairment

• Vials: 500 mg, 1 g, 2 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 2mg

Cefoperazone + Sulbactam for Injection BP

Cefoperazone + Sulbactam for Injection BP is a broad-spectrum beta-lactam antibiotic combination. Cefoperazone is a third-generation cephalosporin, and Sulbactam is a beta-lactamase inhibitor that enhances the efficacy of Cefoperazone against beta-lactamase-producing bacteria.

This combination is effective against Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa, making it suitable for serious systemic infections, resistant bacterial strains, and hospital-acquired infections.

Each vial contains:

• Cefoperazone BP – 1 g / 2 g

• Sulbactam BP – 0.5 g / 1 g

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Cefoperazone + Sulbactam for Injection is indicated for:

1. Severe bacterial infections including:

   • Respiratory tract infections (pneumonia, bronchitis)

   • Urinary tract infections (UTIs)

   • Skin and soft tissue infections

   • Bone and joint infections

   • Intra-abdominal infections

   • Septicemia and bacteremia

   • Meningitis

2. Hospital-acquired infections and resistant bacterial strains

3. Empirical therapy for life-threatening infections before pathogen identification

4. Surgical prophylaxis in high-risk procedures

• Adults: 1.5–3 g (Cefoperazone + Sulbactam) every 12 hours depending on infection severity

• Children: 50–100 mg/kg/day in divided doses

• Route: IV or IM injection

• Administer over recommended infusion time and follow proper reconstitution guidelines

• Dose adjustments may be required in renal or hepatic impairment

• Vials: 1.5 g (1 g + 0.5 g) / 3 g (2 g + 1 g) per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 3 mg

Imipenem + Cilastatin for Injection BP

Imipenem + Cilastatin for Injection BP is a broad-spectrum carbapenem antibiotic combination used for the treatment of serious and multidrug-resistant bacterial infections.

• Imipenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis, causing bacterial cell death.

• Cilastatin is a renal dehydropeptidase inhibitor that prevents the renal metabolism of Imipenem, thereby increasing its effectiveness and bioavailability.

This combination is effective against Gram-positive, Gram-negative, and anaerobic bacteria, including Pseudomonas aeruginosa and other multidrug-resistant organisms. It is commonly used in hospital-acquired infections, complicated intra-abdominal infections, sepsis, and severe systemic infections.

Each vial contains:

• Imipenem BP – 500 mg / 1 g

• Cilastatin BP – 500 mg / 1 g (equal to Imipenem dose)

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Imipenem + Cilastatin for Injection is indicated for:

1. Severe bacterial infections including:

   • Complicated intra-abdominal infections

   • Septicemia and bacteremia

   • Respiratory tract infections (hospital-acquired and ventilator-associated pneumonia)

   • Urinary tract infections (UTIs)

   • Skin and soft tissue infections

   • Bone and joint infections

   • Meningitis

2. Empirical therapy for life-threatening infections before pathogen identification

3. Treatment of infections caused by multidrug-resistant organisms (MDROs)

4. Post-surgical infections

• Adults: 500 mg–1 g (Imipenem component) every 6–8 hours depending on infection severity

• Children: 15–25 mg/kg every 6–8 hours

• Route: IV infusion over 20–30 minutes

• Dose adjustments may be required in renal impairment

• Vials: 500 mg + 500 mg / 1 g + 1 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 1mg

Ertapenem for Injection BP

Ertapenem for Injection BP is a broad-spectrum carbapenem antibiotic used for the treatment of serious bacterial infections.

Ertapenem works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. It is effective against Gram-positive, Gram-negative, and anaerobic bacteria, including multidrug-resistant organisms.

Ertapenem is particularly used in intra-abdominal infections, complicated urinary tract infections, community-acquired pneumonia, skin and soft tissue infections, and surgical prophylaxis.

Each vial contains:

• Ertapenem BP – 1 g

• Excipients: q.s. for injection (lyophilized powder)

After reconstitution with sterile water or suitable diluent, it is ready for intravenous (IV) or intramuscular (IM) injection.

Ertapenem for Injection is indicated for:

1. Complicated intra-abdominal infections

2. Complicated urinary tract infections (UTIs) including pyelonephritis

3. Community-acquired pneumonia

4. Skin and soft tissue infections

5. Surgical prophylaxis in high-risk procedures

6. Empirical therapy for severe infections caused by multidrug-resistant bacteria

• Adults: 1 g once daily, IV or IM, infusion over 30 minutes

• Children: 15 mg/kg once daily (for approved pediatric use)

• Dose adjustments may be required in renal impairment

• Should be administered under medical supervision

• Vials: 1 g per vial

• Lyophilized powder, single-use vials

• Bulk and institutional packaging available

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 1mg

Streptomycin for Injection BP

Streptomycin for Injection BP is an aminoglycoside antibiotic used for the treatment of serious bacterial infections. It acts by inhibiting bacterial protein synthesis, resulting in the death of susceptible bacteria.

This sterile injectable formulation is intended for intramuscular or intravenous administration, making it suitable for hospital use, tuberculosis treatment centers, and clinical settings. Streptomycin is particularly valuable for infections caused by Mycobacterium tuberculosis and other Gram-negative bacterial infections.

Each vial contains:

• Streptomycin Sulfate BP – 1 g / 0.75 g / 0.5 g

• Excipients: q.s. for sterile injection (water for injection or suitable buffer)

• Tuberculosis (TB) – pulmonary and extrapulmonary TB in combination therapy

• Severe Gram-negative bacterial infections – e.g., pneumonia, septicemia, and meningitis

• Endocarditis – as part of combination therapy

• Plague, tularemia, brucellosis, and other rare bacterial infections

• Second-line therapy for drug-resistant TB

• Combination therapy with beta-lactams or other antibiotics for synergistic effect

• Route: Intramuscular (IM) or Intravenous (IV) injection

• Typical Adult Dose: 15 mg/kg/day IM or IV, divided into 1–2 doses, depending on infection severity

• Pediatric Dose: Adjusted by body weight, usually 15 mg/kg/day

• Monitoring: Renal function, auditory function (ototoxicity), and neuromuscular function

⚠ Administer only under specialist supervision

• Available strengths: 0.5 g, 0.75 g, 1 g vials

• Sterile solution for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1 g

Kanamycin for Injection BP

Kanamycin for Injection BP is a broad-spectrum aminoglycoside antibiotic used to treat serious bacterial infections, particularly those caused by Gram-negative bacteria. It works by inhibiting bacterial protein synthesis, leading to bacterial cell death.

This sterile injectable formulation is intended for intramuscular or intravenous administration and is commonly used in hospital settings, TB treatment centers, and specialty clinics. Kanamycin is also used as a second-line therapy for drug-resistant tuberculosis.

Each vial contains:

• Kanamycin Sulfate BP – 500 mg / 750 mg / 1 g

• Excipients: q.s. sterile water for injection

• Severe Gram-negative bacterial infections – e.g., septicemia, pneumonia, urinary tract infections

• Tuberculosis (TB) – particularly multi-drug resistant TB as part of combination therapy

• Endocarditis – in combination with other antibiotics

• Bacterial infections resistant to first-line aminoglycosides

• Intra-abdominal infections, bone and joint infections

• Plague, brucellosis, tularemia (specialist use)

• Route: Intramuscular (IM) or Intravenous (IV) injection

• Typical Adult Dose: 15 mg/kg/day IM or IV, divided into 2–3 doses, depending on infection severity

• Pediatric Dose: Adjusted by body weight, usually 15 mg/kg/day

• Monitoring: Renal function, auditory function (ototoxicity), and neuromuscular function

⚠ Administer only under specialist supervision

• Available strengths: 500 mg, 750 mg, 1 g vials

• Sterile solution for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10 days
• Packaging Details: 1g

Capreomycin for Injection BP

Capreomycin for Injection BP is a polypeptide antibiotic primarily used as a second-line treatment for multi-drug resistant tuberculosis (MDR-TB). It works by inhibiting bacterial protein synthesis, thereby killing Mycobacterium tuberculosis.

This sterile injectable formulation is intended for intramuscular administration under specialist supervision. Capreomycin is particularly valuable in cases of resistance to first-line anti-TB drugs, providing an effective option in tuberculosis treatment programs and hospital settings.

Each vial contains:

• Capreomycin Sulfate BP – 1 g / 500 mg

• Excipients: q.s. sterile water for injection

• Multi-drug resistant tuberculosis (MDR-TB) – pulmonary and extrapulmonary

• Drug-resistant TB cases – in combination therapy with other second-line anti-TB agents

• Adjunct therapy for complicated TB cases

• Second-line therapy in patients intolerant to aminoglycosides like Kanamycin or Streptomycin

• Specialist infectious disease management under hospital supervision

• Route: Intramuscular (IM) injection only

• Typical Adult Dose: 15 mg/kg/day IM, divided into 2 doses or as per TB protocol

• Pediatric Dose: Adjusted according to body weight and clinical response

• Monitoring: Renal function, auditory function (ototoxicity), electrolytes, and injection site reactions

⚠ Administer only under specialist supervision and as part of a TB treatment protocol

• Available strengths: 500 mg, 1 g vials

• Sterile solution for injection

• Bulk and hospital packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Additional Information:

• Production Capacity: 500000
• Delivery Time: 10days
• Packaging Details: 1 g

Cefixime + Ofloxacin Tablets BP – 400 mg

Cefixime + Ofloxacin Tablets BP is a broad-spectrum antibiotic combination used for the treatment of bacterial infections.

• Cefixime (200 mg): A third-generation cephalosporin that inhibits bacterial cell wall synthesis, effective against gram-positive and gram-negative bacteria.

• Ofloxacin (200 mg): A fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial replication and growth.

This synergistic combination provides enhanced antibacterial coverage and is effective in respiratory, urinary, gastrointestinal, and skin infections caused by susceptible bacteria.

Each film-coated tablet contains:

• Cefixime BP – 200 mg

• Ofloxacin BP – 200 mg

• Excipients: q.s.

• Respiratory tract infections (pneumonia, bronchitis)

• Urinary tract infections (UTIs)

• Gastrointestinal infections (typhoid, enteritis)

• Skin and soft tissue infections

• Bone and joint infections

• Sexually transmitted infections (gonorrhea, chlamydia)

• Mixed bacterial infections requiring broad-spectrum coverage

• Route: Oral

• Usual Dose: 1 tablet twice daily, or as prescribed by the physician

• Administration: Take with or without food, preferably with water